NCT02366819 2026-03-30
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
University of Chicago
Phase 4 Suspended
Clinical Trials
9 trialsNCT07446465 2026-03-03
FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer
Fudan University
Phase 4 Not yet recruiting
NCT07094893 2026-01-14
ARIEL-ENGIC
Gruppo Oncologico del Nord-Ovest
Phase 4 Not yet recruiting
NCT06461442 2025-12-05
Efficacy and Safety of Cryotherapy Versus 5-Fluorouracil in the Treatment of Actinic Keratosis
University of California, Davis
Phase 4 Enrolling by invitation
NCT02688803 2025-12-04
OTT15-04
Ottawa Hospital Research Institute
Phase 4 Terminated
NCT07158164 2025-11-13
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
Rutgers, The State University of New Jersey
Phase 4 Recruiting
NCT07014540 2025-06-11
A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma
Beijing GoBroad Hospital
Phase 4 Not yet recruiting
NCT06499415 2025-05-11
CALM
Maastricht University Medical Center
Phase 4 Recruiting
NCT03909646 2025-05-06
BOWTIE
Maastricht University Medical Center
Phase 4 Completed